Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Footnotes
  • Version history
  • Article usage
  • Citations to this article
Advertisement

Corrigendum Free access | 10.1172/jci.insight.130202

Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice

Russell G. Rogers, Mario Fournier, Lizbeth Sanchez, Ahmed G. Ibrahim, Mark A. Aminzadeh, Michael I. Lewis, and Eduardo Marbán

Find articles by Rogers, R. in: JCI | PubMed | Google Scholar

Find articles by Fournier, M. in: JCI | PubMed | Google Scholar

Find articles by Sanchez, L. in: JCI | PubMed | Google Scholar

Find articles by Ibrahim, A. in: JCI | PubMed | Google Scholar

Find articles by Aminzadeh, M. in: JCI | PubMed | Google Scholar

Find articles by Lewis, M. in: JCI | PubMed | Google Scholar

Find articles by Marbán, E. in: JCI | PubMed | Google Scholar

Published June 6, 2019 - More info

Published in Volume 4, Issue 11 on June 6, 2019
JCI Insight. 2019;4(11):e130202. https://doi.org/10.1172/jci.insight.130202.
© 2019 American Society for Clinical Investigation
Published June 6, 2019 - Version history
View PDF

Related article:

Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice
Russell G. Rogers, … , Michael I. Lewis, Eduardo Marbán
Russell G. Rogers, … , Michael I. Lewis, Eduardo Marbán
In a model of muscular dystrophy, cardiosphere-derived cells improve cardiac and skeletal muscle function, partially reverse established heart damage, and boost the regenerative capacity of skeletal muscle.
Research Article Muscle biology Stem cells

Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice

  • Text
  • PDF
Abstract

Dystrophin deficiency leads to progressive muscle degeneration in Duchenne muscular dystrophy (DMD) patients. No known cure exists, and standard care relies on the use of antiinflammatory steroids, which are associated with side effects that complicate long-term use. Here, we report that a single intravenous dose of clinical-stage cardiac stromal cells, called cardiosphere-derived cells (CDCs), improves the dystrophic phenotype in mdx mice. CDCs augment cardiac and skeletal muscle function, partially reverse established heart damage, and boost the regenerative capacity of skeletal muscle. We further demonstrate that CDCs work by secreting exosomes, which normalize gene expression at the transcriptome level, and alter cell signaling and biological processes in mdx hearts and skeletal muscle. The work reported here motivated the ongoing HOPE-2 clinical trial of systemic CDC delivery to DMD patients, and identifies exosomes as next-generation cell-free therapeutic candidates for DMD.

Authors

Russell G. Rogers, Mario Fournier, Lizbeth Sanchez, Ahmed G. Ibrahim, Mark A. Aminzadeh, Michael I. Lewis, Eduardo Marbán

×

Original citation: JCI Insight. 2019;4(7):e125754. https://doi.org/10.1172/jci.insight.125754

Citation for this corrigendum: JCI Insight. 2019;4(11):e130202. https://doi.org/10.1172/jci.insight.130202

Eduardo Marbán’s conflict-of-interest statement was not included in the manuscript. The authors apologize for the oversight. The correct statement is below.

EM declares ownership of Capricor Therapeutics stock (self and spouse) and salary to his spouse from Capricor Therapeutics. He is also the inventor on one awarded (US 9,828,603) and two relevant pending (US 15/516,658 and PCT/US2018/028148) patent applications assigned to Cedars-Sinai Medical Center.

The authors regret the error.

Footnotes

See the related article at Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice.

Version history
  • Version 1 (June 6, 2019): Electronic publication

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Footnotes
  • Version history
Advertisement
Advertisement

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts